Danaher (DHR) to Release Quarterly Earnings on Tuesday

Key Points

• Danaher is set to release its Q3 2025 earnings on October 21st, with analysts predicting earnings of $1.72 per share and revenue of $5.9972 billion.
• The company recently announced a quarterly dividend of $0.32, representing a 0.6% yield, to be paid on October 31st.
• Danaher stock has seen a fluctuation with a 52-week high of $279.41 and a low of $171.00, and currently has a market capitalization of $147.05 billion.

Danaher (NYSE:DHR - Get Free Report) is expected to release its Q3 2025 results before the market opens on Tuesday, October 21st. Analysts expect Danaher to post earnings of $1.72 per share and revenue of $5.9972 billion for the quarter. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS.Investors can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, October 21, 2025 at 8:00 AM ET.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company earned $1.72 earnings per share. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Danaher Price Performance

Shares of NYSE DHR opened at $205.36 on Tuesday. The stock's 50-day simple moving average is $200.82 and its two-hundred day simple moving average is $197.06. Danaher has a twelve month low of $171.00 and a twelve month high of $279.41. The firm has a market capitalization of $147.05 billion, a P/E ratio of 43.69, a P/E/G ratio of 2.88 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio (DPR) is currently 27.23%.

Wall Street Analyst Weigh In

A number of research firms have commented on DHR. Rothschild Redb cut shares of Danaher from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 8th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Danaher in a research report on Wednesday, October 8th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Rothschild & Co Redburn reaffirmed a "neutral" rating and set a $220.00 price target (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Finally, Robert W. Baird increased their price objective on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $244.60.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 11.20% of the company's stock.

Institutional Trading of Danaher

Several hedge funds and other institutional investors have recently bought and sold shares of DHR. WFA of San Diego LLC bought a new position in shares of Danaher in the second quarter worth approximately $26,000. Zuckerman Investment Group LLC purchased a new stake in Danaher during the 2nd quarter valued at $222,000. Gallagher Fiduciary Advisors LLC grew its holdings in Danaher by 7.5% in the 2nd quarter. Gallagher Fiduciary Advisors LLC now owns 1,149 shares of the conglomerate's stock worth $227,000 after acquiring an additional 80 shares during the last quarter. 44 Wealth Management LLC increased its position in shares of Danaher by 7.8% in the second quarter. 44 Wealth Management LLC now owns 1,264 shares of the conglomerate's stock valued at $250,000 after acquiring an additional 92 shares during the period. Finally, HUB Investment Partners LLC raised its stake in shares of Danaher by 30.7% during the second quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate's stock valued at $273,000 after acquiring an additional 325 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.